Trial Profile
A Phase 2 Study of Cisplatin + Pemetrexed + Avastin as First-Line Therapy in Patients With Advanced Non-Squamous, Non-Small Cell Lung Carcinoma.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Nov 2012
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Cisplatin; Pemetrexed
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 01 Oct 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 29 Oct 2009 New trial record